Litcius/Paper detail

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Philippe A. Cassier, Marwan Fakih, Steven Kao, Dorte Nielsen, Antoîne Italiano, Tormod Kyrre Guren, Marloes G. J. van Dongen, Kristen Spencer, Giovanni M. Bariani, Paolo A. Ascierto, Armando Santoro, Manisha H. Shah, Jamil Asselah, Syma Iqbal, Shunji Takahashi, Sarina A. Piha‐Paul, Patrick A. Ott, Arkendu Chatterjee, Fan Jin, Kevin Norwood, Jean‐Pierre Delord

2022˜The œLancet. Gastroenterology & hepatology73 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePembrolizumabInternal medicineClinical endpointAnal cancerCohortAdverse effectSurgeryCancerPhases of clinical researchClinical trialOncologyImmunotherapyColorectal and Anal CarcinomasCancer Immunotherapy and BiomarkersIntraperitoneal and Appendiceal Malignancies